Cure Parkinson’s and Alzheimer’s Research UK announce a partnership
Cure Parkinson’s and Alzheimer’s Research UK are working on an initiative that could pave the way for innovative neurodegenerative treatments. There is a growing recognition that tackling neurodegenerative diseases could benefit from a collaborative, cross-disease approach. We are recognising the overlap in underlying biological...
Learn more
Spring Research Update Meeting 2022 – recorded to watch again
Theme: Why diabetes drugs might be an important potential line of treatment for Parkinson’s. The meeting was recorded and is available to re-watch now
New mRNA activators for Parkinson’s
Research evidence has suggested that in Parkinson’s there is some disruption to a process involved in protein production within cells. This process is known as ‘m6A mRNA methylation’, and activation of this process may protect nerve cells against Parkinson’s. Laboratory research has shown that supporting…
The lonafarnib pre-clinical study
This research led by Professor Joe Mazzulli, will, it is hoped, give us a better understanding of how lonafarnib can reduce the build-up of the toxic protein alpha-synuclein which is a characteristic of Parkinson’s.
Liraglutide trial: results
Researchers from Cedars Sinai Hospital, Los Angeles have presented their initial top line results of the liraglutide trial, co-funded by Van Andel Institute and Cure Parkinson’s, at the recent American Association of Neurology annual meeting. The results indicate that liraglutide improves aspects of daily living…
Nicotinamide riboside for Parkinson’s: pilot results published
Researchers in Norway have published the promising results of a pilot clinical study of nicotinamide riboside for people with Parkinson’s.